199 related articles for article (PubMed ID: 3263037)
41. Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
Conti JA; Kemeny NE; Saltz LB; André AM; Grossano DD; Bertino JR
Cancer; 1995 Feb; 75(3):769-74. PubMed ID: 7828126
[TBL] [Abstract][Full Text] [Related]
42. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.
De Gramont A; Krulik M; Cady J; Lagadec B; Maisani JE; Loiseau JP; Grange JD; Gonzalez-Canali G; Demuynck B; Louvet C
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1499-503. PubMed ID: 3263275
[TBL] [Abstract][Full Text] [Related]
43. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
[TBL] [Abstract][Full Text] [Related]
44. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer.
Hartung G; Hofheinz RD; Wein A; Riedel C; Rost A; Fritze D; Kreuser ED; Drees M; Kühnel J; Hehlmann R; Queisser W
Onkologie; 2001 Oct; 24(5):457-62. PubMed ID: 11694772
[TBL] [Abstract][Full Text] [Related]
46. High and low dose folinic acid, 5-fluorouracil bolus and continuous infusion for poor-prognosis patients with advanced colorectal carcinoma.
Bano N; Najam R; Mateen A; Qazi F
Asian Pac J Cancer Prev; 2012; 13(8):3589-93. PubMed ID: 23098438
[TBL] [Abstract][Full Text] [Related]
47. 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
Fried G; Tsalik M; Stein M; Dale J; Haim N
Cancer Chemother Pharmacol; 1995; 35(5):437-40. PubMed ID: 7850927
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
49. A phase II trial of 5-fluorouracil, leucovorin and mitomycin C in patients with advanced gastric cancer.
Kim SR; Yuh YJ; Sohn BS; Yang SH
Tumori; 2011; 97(6):698-703. PubMed ID: 22322834
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Kuo T; Cho CD; Halsey J; Wakelee HA; Advani RH; Ford JM; Fisher GA; Sikic BI
J Clin Oncol; 2005 Aug; 23(24):5613-9. PubMed ID: 16110021
[TBL] [Abstract][Full Text] [Related]
51. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
52. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
53. Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Delaunoit T; Maréchal R; Hendlisz A; Eisendrath P; Legendre H; Pector JC; De Becker D; Bleiberg H
Anticancer Drugs; 2004 Aug; 15(7):725-8. PubMed ID: 15269605
[TBL] [Abstract][Full Text] [Related]
54. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
[TBL] [Abstract][Full Text] [Related]
55. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers.
Yeh KH; Cheng AL; Lin MT; Hong RL; Hsu CH; Lin JF; Chang KJ; Lee PH; Chen YC
Anticancer Res; 1997; 17(5B):3867-71. PubMed ID: 9427794
[TBL] [Abstract][Full Text] [Related]
56. Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.
Klaassen U; Wilke H; Müller C; Borquez D; Korn M; Achterrath W; Harstrick A; Diergarten K; Seeber S
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):38-40. PubMed ID: 9144690
[TBL] [Abstract][Full Text] [Related]
57. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
Goldberg RM; Hatfield AK; Kahn M; Sargent DJ; Knost JA; O'Connell MJ; Krook JE; Maillard JA; Wiesenfeld M; Schaefer PL; Tirona MT; Moertel CG
J Clin Oncol; 1997 Nov; 15(11):3320-9. PubMed ID: 9363861
[TBL] [Abstract][Full Text] [Related]
58. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Köhne CH; Hiddemann W; Schüller J; Weiss J; Lohrmann HP; Schmitz-Hübner U; Bodenstein H; Schöber C; Wilke H; Grem J
J Clin Oncol; 1995 May; 13(5):1201-8. PubMed ID: 7738622
[TBL] [Abstract][Full Text] [Related]
59. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).
Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD
Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873
[TBL] [Abstract][Full Text] [Related]
60. Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.
Köhne CH; Wilke H; Hiddemann W; Bokemeyer C; Lohrmann HP; Bodenstein H; Preiss J; Rauschecker H; Hill H; Kaufer C; Fischer JT; Ohl U; Urbanitz D; Balleisen L; Schmoll HJ
Oncology; 1997; 54(2):96-101. PubMed ID: 9075778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
